The key companies analyzed in the report include AbbVie Inc., Novartis AG, Amgen Inc., AstraZeneca plc., Abbott Laboratories, UCB S.A, F. Hoffmann-La Roche AG, Johnson & Johnson, Bristol-Myers Squibb Company, and Pfizer Inc., Adhering to a number of exclusive strategies, these key players have been successful in maintaining their top status in the market. They are also expanding the scope of their business operations by incorporating innovative products in their product portfolios.
The Global Autoimmune Disease Therapeutics Market is expected to hit $153.3 billion by 2025, growing at a CAGR of 4.2% during the study period.
The report segments the market into drug class, indication, sales channel and region. The drug class segment is classified into anti-inflammatory, antithyperglycemics, sales channel and region. Based on indication, the market is categorized into Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on region, the market is analyzed across various regions including North America, Asia-Pacific, Europe, and Latin America, Middle East and Africa (LAMEA).
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/5185
Surge in adoption of autoimmune disease therapeutics, increase in the prevalence of autoimmune disease, and wise availability of advanced therapeutics have fueled the growth of the global autoimmune disease therapeutics market. On the other hand, higher cost associated with the therapeutics has checked the growth to some extent. However, growth prospects in emerging economies, and strong presence of pipeline drugs have created multiple opportunities in the segment.
By drug class, the anti-inflammatory segment accounted for the major revenue in 2017, and is expected to rule the roost throughout the study period. Rise in demand for anti- inflammatory drugs, and launch of newer anti- inflammatory drugs with the supportive reimbursement policies have spurred the growth.
By indication, the rheumatic disease segment contributed to the biggest share in 2017 and is anticipated to maintain its dominance during the forecast period. This is due to the growing incidence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, and polymyalgia rheumatic.
Based on sales channel, the online store segment is anticipated to grow at the highest CAGR during the forecast period. This is driven by the growing preference for online purchasing of drugs over the traditional methods and increase in awareness about online pharmacy.
Related Reports:
About Us:-
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact Us:-
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
